Form 4: Cytek Biosciences SVP Philippe Busque Reports Stock Transactions
SEC Form 4 Filing
Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, reported the vesting and subsequent sale of shares to cover tax obligations related to restricted stock units.
Summary
- On August 19, 2024, Philippe Busque, SVP of Global Sales and Services at Cytek Biosciences, engaged in transactions involving common stock and restricted stock units (RSUs).
- Busque exercised RSUs, acquiring 1,536 and 2,210 shares of common stock.
- Simultaneously, 599 and 861 shares were withheld by Cytek Biosciences to satisfy tax obligations at a price of $5.53 per share.
- Following these transactions, Busque directly owns 10,585 shares of common stock and holds 31,677 RSUs.
Sentiment
Score: 5
Explanation: This is a neutral filing reflecting routine stock transactions related to executive compensation.
Industry Context
Form 4 filings are a routine part of compliance for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they involve the vesting of previously granted equity.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of stock transactions (exercise of RSUs and tax withholding). |
| 08/21/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.